Silvestri is co-leading this collaboratory, and PAVE co-lead Ann Chahroudi, MD, PhD, is a co-investigator. This collaboratory, one of the two original Martin Delaney Collaboratory programs, will work with academic scientists and clinicians, industry investigators and the community to better understand persistent HIV infection and discover novel approaches to disrupt HIV latency, methods to clear the HIV reservoir and strategies to control viral rebound. ![]() Collaboratory of AIDS Researchers for Eradication (CARE), led by University of North Carolina at Chapel Hill.Pediatric Adolescent Virus Elimination (PAVE), co-led by Emory and Johns Hopkins University, and the only collaboratory focusing on curing pediatric HIV.In addition to ERASE HIV, the Emory/Yerkes researchers also hold leading roles in three other newly awarded Martin Delaney Collaboratories: “The Atlanta-based organization leads community-based initiatives in HIV prevention, treatment and care, and will be instrumental in sharing ERASE HIV research advancements with all those SisterLove educates, inspires and serves.” “We are fortunate to work with SisterLove, Inc., the first women’s HIV/AIDS and reproductive justice organization in the Southeastern United States,” Kulpa adds. “This NIH funding gives us the opportunity to build on Emory’s eminence as a worldwide leader in HIV/AIDS research and to assemble an incredible team of researchers and community advocates for the ERASE HIV Collaboratory. “Antiretroviral therapy has literally been a lifesaver for millions of people living with HIV around the world, but our work is not finished,” says Kulpa. The virus hides in the body and rebounds when people with HIV stop taking ART. While ART has been successful in reducing HIV to undetectable levels and halting the progression to AIDS, the treatment does not eliminate HIV. “This knowledge will help us develop immunological-based therapies that could provide additional treatment options for other infectious diseases as well as cancer.” “HIV cure research is also important for increasing overall understanding of the immune system,” Paiardini continues. Our work and the work of the other Martin Delaney Collaboratories will bring us closer to a cure, a goal now regarded as possible based on recent research advancements and the continuing dedication of HIV/AIDS researchers and advocates. “Since then, more than 700,000 people in America have died from HIV-related illness, and a similar number died worldwide just in the last year. “It’s been 40 years since the first case of what we now know as HIV/AIDS was reported in the United States,” says Paiardini. Silvestri is Yerkes division chief of microbiology and immunology, Emory SOM professor and chair of the Department of Pathology and Laboratory Medicine, and a Georgia Research Alliance Eminent Scholar. ![]() Paiardini is contact principal investigator for ERASE HIV and also a Yerkes researcher and Emory SOM professor of pathology and laboratory medicine. Kulpa is a Yerkes researcher and assistant professor of pathology and laboratory medicine in the Emory School of Medicine (SOM). As part of ERASE HIV, they will characterize the key immune system functions that control persistent HIV infection and design innovative, immune-based therapies to eliminate or control the virus in the absence of antiretroviral therapy (ART). These leaders and their team members are renowned for their HIV cure research. The Emory/ Yerkes NPRC study leaders are Deanna Kulpa, PhD Mirko Paiardini, PhD and Guido Silvestri, MD. The Enterprise for Research and Advocacy to Stop and Eradicate HIV (ERASE HIV) is one of the 10 newly NIH-funded Martin Delaney Collaboratories for HIV Cure and the only one researchers at a National Primate Research Center (NPRC) are leading. ATLANTA – An Emory University-led research collaboration has been awarded a five-year, $23.8 million grant from the National Institutes of Health (NIH) to fast-track research to cure HIV infection or put it in permanent remission.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |